Every barrier is a yield term
Ex-vivo manufacture multiplies collection, enrichment, editor delivery, viability, expansion, formulation, release, logistics, and administration. In vivo, formulation, circulation, organ distribution, cell entry, endosomal escape, intracellular trafficking, expression, immunity, and clearance multiply instead. Raising dose cannot repair every loss because off-target exposure and toxicity rise too.
Three numbers that locate the frontier
The endosomal-escape estimate is literature- and cargo-dependent. Editing and biodistribution vary with chemistry, route, species, tissue, dose, assay, and disease; no universal efficiency is implied.
Measure functional target cells per tolerated released dose
Edit percentage, bulk organ signal, or particle uptake can each hide the wrong cell type, dead cells, nonfunctional compartments, heterogeneous potency, or damaging off-target exposure. The curve must preserve cell function and clinical benefit-risk.
Autologous ex-vivo products reduce immune mismatch but create patient-specific scheduling and starting-material variability.
In-vivo delivery can scale as a vial but must solve biodistribution, intracellular release, immune response, duration, and redosing.
The headline metric sits on a system
Each layer can become the bottleneck even when the layer before it improves.
Payload and formulation
Editor, guide, template or transgene, vector chemistry, dose, route, and stability define the administered material.
- Measure
- Identity · activity · stability
- Failure mode
- Payload and manufacturing limits
Biological delivery
Transfection or transduction ex vivo; circulation, tissue access, cell targeting, entry, escape, and trafficking in vivo.
- Measure
- Functional target-cell exposure
- Failure mode
- Losses and off-target distribution
Editing and cell function
On-target change, editor duration, chromosomal integrity, viability, phenotype, expression, and potency determine useful action.
- Measure
- Potent correctly edited cells
- Failure mode
- Off-target and heterogeneous response
Release and clinical delivery
Expansion or fill, formulation, sterility, potency assays, logistics, conditioning, administration, monitoring, and redosing complete the medicine.
- Measure
- Released doses · therapeutic window
- Failure mode
- Testing, immunity, and care burden
Specificity and manufacturing yield are both ratios
Targeting rarely sends every particle to one cell type, and living products cannot be destructively inspected in full. Therapeutic design must establish a window between effective target exposure and harmful off-target exposure while preserving enough product through every operation.
Programmable payloads move scarcity into tissue access and evidence
As editors become easier to design, each target tissue and product still needs characterized delivery, toxicology, genomic safety, potency, manufacture, comparability, clinical workflow, and long-term follow-up.
Match branch to disease
Choose ex vivo when cells can be collected and returned; choose in vivo when anatomy and scale justify direct delivery.
Limit active exposure
Use transient editors and controlled expression when durability is not required.
Design for escape and specificity
Measure target-cell function, not bulk uptake, and suppress activity in off-target cells.
Build a release platform
Reuse closed processing, analytics, potency assays, and delivery knowledge across related products.
An optimistic view, with conditions
Gene medicine becomes a library of validated delivery platforms
The highest leverage comes from tissue and cell platforms whose tropism, intracellular release, editor compatibility, manufacture, safety, assays, and clinical workflow can support families of payloads.
Sources, method, and boundaries
Regulatory distinctions and safety considerations follow FDA guidance. Quantitative delivery claims retain their experimental boundaries. The yield-chain framing combines ex-vivo manufacturing and in-vivo biodistribution without treating them as interchangeable processes.
